This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $999,998 to Antlia Bioscience, Inc. to develop a novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (HBNP), to treat resistant hypertension. Specifically, the funding will support bulk manufacture of the clinical-grade PAS(400)-HBNP compound, dose-ranging pharmacokinetic and pharmacodynamic studies in animal models, and safety assessments in GLP-toxicity and cardiovascular safety studies. This work aims to address the challenge of HBNP's rapid elimination from the blood, which has previously limited its therapeutic effectiveness. By extending the lifespan of HBNP using a proline-alanine-serine polymer, Antlia Bioscience intends to produce a long-acting formulation suitable for up to biweekly dosing in humans, with the goal of effectively treating resistant hypertension. The award commenced on September 19, 2024 and is expected to be complete by June 30, 2027.
Generated 1/28/25, 9:41 AM